datascale

Search services, integrations and blog posts.

Healthcare Media

Veeva Crossix Measurement: What It Does, What Replaces It Here

In US pharma media, Crossix is the yardstick. The look pays off from DACH too, precisely because the model does not exist here.

What Veeva Crossix is

Crossix is Veeva's measurement platform for US healthcare marketing. It buys no media and supplies no audiences; it measures impact: how well a campaign reached the right people, and whether prescribing behaviour moves afterwards. The foundation is a US health data network of prescription, claims and treatment signals that, per the vendor, spans several hundred million patient profiles.

Two metrics carry the system. Audience Quality scores, before and during the flight, what share of the reached people fit the addressed treatment situation. Rx lift measures afterwards whether the exposed group prescribes or stays adherent more often than a comparable control group. Both run through matching, not through individual-person reports.

How the measurement works

The flow is always the same: campaign contacts get matched against health signals inside the network, aggregated, and scored against a control group. The vendor markets this as privacy-safe within the HIPAA frame, using de-identification. That is a vendor statement; its methodology access, the match rate and the control-group design belong in every contract, otherwise you are scoring a black box.

Why the model does not travel to the EEA

The person-level linkage of health data that carries Crossix is not reproducible in the EEA. Health data are Article 9 GDPR categories, and no lawful commercial matching route exists here for prescription and treatment signals. No vendor setup changes that. Anyone promising a Crossix equivalent in DACH has earned double scepticism and a legal review before the first conversation.

How Crossix measures (the US model)

Four stations, one data network. Every metric comes from aggregated matching, not individual-person reports.

  1. Input

    Campaign contacts

    Impressions and clicks from the media buy are passed to the network as pseudonyms.

  2. Match

    US health data network

    Matched against prescription, claims and treatment signals, de-identified within the HIPAA frame per the vendor.

  3. Model

    Control group & lift

    The exposed group is scored against a comparable control group, results aggregated.

  4. Output

    Audience Quality & Rx lift

    Audience fit before the buy, prescribing and adherence impact after it.

The DACH measurement chain we build

No prescription signal, but your own data and a clean impact design. The chain belongs to you, not to a data network.

  1. Capture

    Server-side events

    Content depth, inquiry, professional registration as one event schema across every channel.

  2. Consent

    Consent logic

    Consent Mode V2, dedup, delivery only on a valid legal basis.

  3. Store

    Your own warehouse

    BigQuery as the single source of truth; platform reports stay a source, never the truth.

  4. Model

    Area holdout

    Regions with and without the campaign compared, with aggregation thresholds against re-identification.

Crossix against the DACH measurement chain

Same goal, two foundations. Legal review per market stays mandatory either way.

DimensionVeeva Crossix (US)DACH measurement chain (Datascale)
Data foundationUS health data network: prescriptions, claims, treatmentYour own first-party events plus area signals
What it provesRx lift and audience qualityInquiry and lead impact, regional effect via holdouts
Legal basisHIPAA de-identification (vendor stated)GDPR consent plus aggregation, no person-level health data
Who owns the dataThe vendor's networkYou, in your own warehouse
AvailabilityUS onlyDACH and the EEA
Who runs itVendor plus media partnersYour stack, your team, built by us

Where this question comes up

Three situations where teams reach out to us about Crossix.

US pharma brand team

A brand plans US media and receives Crossix lift numbers from the agency.

Our routeWe check the lift claims against methodology, match rate and control group, and write the access rights into the contract.

DACH launch without Rx data

A biotech launches regionally in DACH, where prescription data is not available.

Our routeWe design an area holdout plus a first-party conversion chain that proves the regional effect honestly.

Global team, one dashboard

The US measures through Crossix, DACH through holdouts, and reporting has to reconcile.

Our routeWe unify taxonomy and events so both worlds read side by side in one dashboard, without a shared person-level chain.

What we build for it

Datascale buys no media and runs no campaigns. We build the measurement layer underneath: tagging, taxonomy, delivery, impact design.

  • Tagging & event schema

    One naming convention across every platform: content engagement, inquiry, professional registration as defined events, delivered server-side and deduplicated.

  • Media assignment & taxonomy

    Audience, market and channel in one consistent structure, so platform reports and the warehouse can reconcile at all.

  • Server-side conversion delivery

    Consent-governed events into the warehouse and the ad platforms, with Consent Mode V2 and dedup.

  • Area holdout design

    The impact model that stands in for Rx lift, including aggregation thresholds against re-identification.

  • One dashboard

    Platform-agnostic reporting from your own warehouse, instead of six separate platform surfaces.

Go deeper

Which measurement chain replaces Rx data in your DACH plan?

HCP Campaign Tracking Audit →

More from this cluster

  • Q01
    What is Veeva Crossix?

    Crossix is Veeva's measurement platform for US healthcare marketing. It measures campaign impact through a US health data network of prescription, claims and treatment signals. It buys no media and supplies no audiences.

  • Q02
    What does Crossix actually measure?

    Two metrics: Audience Quality, meaning how well the reached people fit the treatment situation, and Rx lift, meaning whether the exposed group prescribes more often than a control group. Both come from aggregated matching.

  • Q03
    Is Crossix available in Germany or Europe?

    No. The model rests on linking person-level health data, which is not lawful in the EEA. Prescription and treatment signals fall under Article 9 GDPR, and no commercial matching route exists here for them.

  • Q04
    Is Crossix HIPAA compliant and privacy-safe?

    The vendor markets Crossix as privacy-safe within the HIPAA frame, using de-identification. That is a vendor statement. Methodology access, match rate and control-group design should be reviewed before signing.

  • Q05
    What replaces Crossix measurement in DACH?

    Your own measurement chain: server-side events, consent-governed delivery into your own warehouse, and area holdouts as the impact design. It measures no prescriptions, but inquiry, lead and regional effects, and the data belongs to you.

  • Q06
    Does Crossix buy media?

    No. Crossix is measurement, not a DSP. In practice it shows up next to buying platforms such as DeepIntent, which integrate Rx lift evidence through partners like it.

Architecture audit

Identify the blind spots in your data architecture.

We audit your tracking, consent, data quality and reporting. You leave with a clear assessment of which decisions your current data can safely support. First call within 48 hours.

  • 90-min deep dive
  • Concrete findings
  • Roadmap proposal